Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651229 | 0.84 | RIPK1 (0.42) | RIPK1LMNA | |
| SCHEMBL5647255 | 0.80 | RIPK1 (0.41) | RIPK1LMNA | |
| SCHEMBL2589767 | 0.79 | LTB4R2 (0.43) | RIPK1FFAR4LTB4R2ALDH1A1LMNA | |
| SCHEMBL5648402 | 0.79 | RIPK1 (0.38) | RIPK1LMNA | |
| SCHEMBL25242302 | 0.78 | RIPK1 (0.39) | RIPK1LMNA | |
| SCHEMBL3755629 | 0.76 | KCNA5 (0.45) | KCNA5RIPK1LTB4R2ALDH1A1LMNA | |
| SCHEMBL25242324 | 0.75 | RIPK1 (0.37) | RIPK1LMNA | |
| SCHEMBL25290263 | 0.75 | RIPK1 (0.37) | RIPK1ALDH1A1LMNA | |
| SCHEMBL2588592 | 0.75 | SNCA (0.41) | LTB4R2ALDH1A1LMNAMAPT | |
| SCHEMBL25286462 | 0.74 | RIPK1 (0.36) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | KCNA5 72/4885RIPK1 3747/4885FFAR4 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.